Pros and cons of dabigatran

American Journal of Health-System Pharmacy

Volumn 68, Issue 16, 2011, Pages 1495-

  Cheng, Christine M ^a   McCurdy, Megan R ^a   Wong, Heather A ^a   Kayser, Steven R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVORAXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; DIALYSIS; DIURESIS; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MONITORING; DRUG OVERDOSE; DRUG PACKAGING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; EMBOLISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM;

EID: 80051881912     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110178     Document Type: Editorial

References (3)

1. Pradaxa (dabigatran etexilate) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2010.
2. Van Ryn J., Stangier J., Haertter S. et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-1127
3. Wallentin L., Yusuf S., Ezekowitz M.D. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010; 376:975-983